Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

Exclusion Criteria

• •Severe cardiac or pulmonary insufficiency, which the investigator deems inappropriate for enrollment.
• •Complicated with other progressive malignant tumors.
• •Presence of active and/or uncontrolled infections that have not been effectively managed.
• •Complicated with severe autoimmune diseases or congenital immunodeficiency.
• •Active hepatitis \[positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), with HBV DNA copy number greater than the upper limit of normal at the study center; positive for anti-HCV, with HCV-RNA copy number greater than the upper limit of normal at the study center\].
• •Human immunodeficiency virus (HIV) infection or known acquired immune deficiency syndrome (AIDS), syphilis infection.).
• •A history of severe hypersensitivity to biological products (including antibiotics).
• •Patients who have undergone allogeneic hematopoietic stem cell transplantation and still suffer from acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents.
• •Patients with other severe physical or mental diseases or abnormal laboratory test results that may increase the risk of study participation or interfere with study outcomes, as well as those who are deemed unsuitable for participation in this study by the investigator.